newest glp-1 drugs What to Make of the Coverage and Cost Landscape The next generation of GLP-1

Potential mechanisms Mol Metab

Advantage : Survodutide MASH / Liver Disease# Pemvidutide : Phase 2b IMPACT trial showed 59.1% MASH resolution at 1.2 mg and 52.1% at 1.8 mg vs 19.1% placebo at 24 weeks

But if I see someone who's lived with obesity for a long period of time, like years as we said, years living with obesity I'm going to pay very close attention to them about their disease risk

In our experience, weight loss usually continues for 912 months

SURMOUNT-1 data showed 22.5% average body weight reduction at this dose over 72 weeks

By enhancing autophagy and stabilizing mitochondria indirectly via AMPK and SIRT, GLP-1RAs may also act as indirect suppressors of pathological STING activation